Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 87

Sort by

Sort Order Select

Journal Articles

Patterns of care and outcomes in patients with large B-cell lymphoma not treated with full-dose anthracycline regimens: Outcome analysis from the lymphoma epidemiology of outcomes (LEO) prospective cohort study

Blood (2025) 146 (Supplement 1): 6312.

https://doi.org/10.1182/blood-2025-6312

Published: 2025

Journal Articles

Shorter diagnosis to treatment interval is associated with poor prognosis in patients with peripheral T-cell lymphoma: Analysis from the LEO and MER cohorts

Blood (2025) 146 (Supplement 1): 5439.

https://doi.org/10.1182/blood-2025-5439

Published: 2025

Journal Articles

A Phase 1 study of KITE-753 or KITE-363 in patients with relapsed/refractory B-cell lymphoma: Initial safety and preliminary efficacy of KITE-753 and updated results of KITE-363

Blood (2025) 146 (Supplement 1): 265.

https://doi.org/10.1182/blood-2025-265

Published: 2025

Journal Articles

Outcomes of CAR T-cell therapies after prior treatment with fixed-duration mosunetuzumab in patients with relapsed/refractory B-cell non-Hodgkin lymphoma

Adam Braun, Nancy Bartlett, Dai Chihara, Loretta Nastoupil, Mazyar Shadman, Dimitrios Tzachanis, Hunter Cochran, Jennifer Huang, Mei Wu, Michael C. Wei, Shen Yin, Jing Qi Hao, Qian Zhu, Yong Mun, Elizabeth Budde

Blood (2025) 146 (Supplement 1): 6261.

https://doi.org/10.1182/blood-2025-6261

Published: 2025

Journal Articles

FLP-R: A clinical prediction model for follicular lymphoma Prognosis in the Relapsed/refractory setting

Blood (2025) 146 (Supplement 1): 5354.

https://doi.org/10.1182/blood-2025-5354

Published: 2025

Journal Articles

Impact of putative cell of origin on CD19+CAR-T outcomes in patients with large B-cell lymphoma

Blood (2025) 146 (Supplement 1): 5500.

https://doi.org/10.1182/blood-2025-5500

Published: 2025

Journal Articles

Clinical outcomes of tisagenlecleucel in patients with relapsed/refractory follicular lymphoma (r/r FL): Phase 2 ELARA 5-year update

Blood (2025) 146 (Supplement 1): 468.

https://doi.org/10.1182/blood-2025-468

Published: 2025

Journal Articles

Blunted CD40-responsive enhancer activation in CREBBP -mutant lymphomas can be restored by enforced CD4 T-cell engagement

Blood (2025) 146 (2): 191–205.

https://doi.org/10.1182/blood.2024026664

Published: 2025

Includes: Supplemental data

Journal Articles

Golcadomide (GOLCA) ± Rituximab (RTX) Demonstrates Durable Efficacy and Is Well Tolerated in Patients (pts) with Relapsed/Refractory Follicular Lymphoma (R/R FL): Updated Results from the Phase 1/2 CC-99282-NHL-001 Study

Julio C. Chavez, Guilherme Fleury Perini, Loretta Nastoupil, Judit Mészáros Joergensen, Pierre Bories, Bijou Fontanet, Pier Luigi Zinzani, Javier Munoz, Daniel Morillo Giles, Cecilia Carpio, Abel Costa, Won Seog Kim, Parth Rao, Bérengère de Moucheron, Yang Gang, Carla Guarinos, Akshay Sudhindra, Michael Pourdehnad, Jean-Marie Michot

Blood (2024) 144 (Supplement 1): 3018.

https://doi.org/10.1182/blood-2024-203131

Published: 2024

Journal Articles

Frontline R-CHOP and BR Have Similar Outcomes By SUV max in Follicular Lymphoma

Blood (2024) 144 (Supplement 1): 3007.

https://doi.org/10.1182/blood-2024-202088

Published: 2024

Journal Articles

Impact of Pre-Existing Mental Health Disorders (MHD) on CAR T-Cell Therapy Outcomes in Patients with Large B-Cell Lymphoma

Blood (2024) 144 (Supplement 1): 4508.

https://doi.org/10.1182/blood-2024-198053

Published: 2024

Journal Articles

Impact of Pre-Treatment Liver-Related Factors on Clinical Outcomes after CAR T-Cell Therapy for Lymphoma

Blood (2024) 144 (Supplement 1): 4506.

https://doi.org/10.1182/blood-2024-207616

Published: 2024

Journal Articles

Identifying the Barriers of Clinical Trial Access after CAR T-Cell Therapy in Relapsed/Refractory Large B-Cell Lymphoma

Kunhwa Kim, Amy Ayers, Sairah Ahmed, Linda Claret, Paolo Strati, Ranjit Nair, Chijioke Nze, Jeremy Ramdial, Janet Torres, Elizabeth J. Shpall, Luis E. Fayad, Loretta Nastoupil, Jason R. Westin, Christopher R. Flowers, Sattva S. Neelapu, Dai Chihara

Blood (2024) 144 (Supplement 1): 5121.

https://doi.org/10.1182/blood-2024-211023

Published: 2024

Journal Articles

Longer Follow-up of Golcadomide (GOLCA), a Cereblon E3 Ligase Modulator (CELMoD™) Agent ± Rituximab (RTX), in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Jean-Marie Michot, Franck Morschhauser, Silvia Ferrari, Judit Mészáros Jørgensen, Loretta Nastoupil, Emmanuel Bachy, Michael Pourdehnad, Akshay Sudhindra, Alev Akyol, Bérengère de Moucheron, Soraya Carrancio, Jessica Voetsch, Xirong Zheng, Julio C. Chavez

Blood (2024) 144 (Supplement 1): 869.

https://doi.org/10.1182/blood-2024-203163

Published: 2024

Journal Articles

Three-Factor Prediction Model for Grade 2+ Cytokine Release Syndrome in Large B-Cell Lymphoma Patients Receiving Epcoritamab Monotherapy

Catherine Thieblemont, Yasmin H. Karimi, Chan Y Cheah, Michael Roost Clausen, Kim Linton, Tycel J. Phillips, Franck Morschhauser, Martin Hutchings, Rebekah Conlon, Saurabh Mukhopadhyay, Aurelie Le Maitre, Yu Deng, Mariana Sacchi, Thomas Doerr, Minh Dinh, William Palo, Loretta Nastoupil

Blood (2024) 144 (Supplement 1): 4491.

https://doi.org/10.1182/blood-2024-200957

Published: 2024

Journal Articles

Lisocabtagene Maraleucel (liso-cel) in Patients (pts) with Relapsed or Refractory (R/R) Follicular Lymphoma (FL): Transcend FL 2-Year Follow-up

Blood (2024) 144 (Supplement 1): 4387.

https://doi.org/10.1182/blood-2024-198509

Published: 2024

Journal Articles

Treatment Patterns and Real World Outcomes with Clinical Trials for Patients with Follicular Lymphoma across Lines of Therapy

Neha Akkad, Amy Ayers, Kumudha Balakrishnan, Loretta Nastoupil, Dai Chihara, Luis Malpica, Paolo Strati, Ziyi Li, Christopher R. Flowers

Blood (2024) 144 (Supplement 1): 4396.

https://doi.org/10.1182/blood-2024-201804

Published: 2024

Journal Articles

Real-World Effectiveness of Tafasitamab (Tafa) for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) in the United States

Kimberly Saverno, Loretta Nastoupil, Bruce Feinberg, John Galvin, Prathamesh Pathak, Theresa Amoloja, Danielle Gentile, Parisa Asgarisabet, Narendranath Epperla

Blood (2024) 144 (Supplement 1): 2375.

https://doi.org/10.1182/blood-2024-193264

Published: 2024

Journal Articles

Real-World Predictors of Financial Toxicity in Patients with Lymphoma

Blood (2024) 144 (Supplement 1): 3754.

https://doi.org/10.1182/blood-2024-201896

Published: 2024

Journal Articles

Cell-Intrinsic and Immune-Mediated Effects in Lymphoma Patients Treated with Golcadomide and Associations with Treatment Outcome

Soraya Carrancio, Jessica Voetsch, Alberto Risueño, Carla Guarinos, Siddhesh Kulkarni, Mandeep Takhar, Matthew E. Stokes, Bérengère de Moucheron, Laura Furman, Julio C. Chavez, Jean-Marie Michot, Loretta Nastoupil, Daniel W. Pierce, Danielle Greenawalt, Michael Pourdehnad

Blood (2024) 144 (Supplement 1): 3104.

https://doi.org/10.1182/blood-2024-203139

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Patterns of care and outcomes in patients with large B-cell lymphoma not treated with full-dose anthracycline regimens: Outcome analysis from the lymphoma epidemiology of outcomes (LEO) prospective cohort study

Shorter diagnosis to treatment interval is associated with poor prognosis in patients with peripheral T-cell lymphoma: Analysis from the LEO and MER cohorts

A Phase 1 study of KITE-753 or KITE-363 in patients with relapsed/refractory B-cell lymphoma: Initial safety and preliminary efficacy of KITE-753 and updated results of KITE-363

Outcomes of CAR T-cell therapies after prior treatment with fixed-duration mosunetuzumab in patients with relapsed/refractory B-cell non-Hodgkin lymphoma

FLP-R: A clinical prediction model for follicular lymphoma Prognosis in the Relapsed/refractory setting

Impact of putative cell of origin on CD19+CAR-T outcomes in patients with large B-cell lymphoma

Clinical outcomes of tisagenlecleucel in patients with relapsed/refractory follicular lymphoma (r/r FL): Phase 2 ELARA 5-year update

Blunted CD40-responsive enhancer activation in CREBBP -mutant lymphomas can be restored by enforced CD4 T-cell engagement

Golcadomide (GOLCA) ± Rituximab (RTX) Demonstrates Durable Efficacy and Is Well Tolerated in Patients (pts) with Relapsed/Refractory Follicular Lymphoma (R/R FL): Updated Results from the Phase 1/2 CC-99282-NHL-001 Study

Frontline R-CHOP and BR Have Similar Outcomes By SUV max in Follicular Lymphoma

Impact of Pre-Existing Mental Health Disorders (MHD) on CAR T-Cell Therapy Outcomes in Patients with Large B-Cell Lymphoma

Impact of Pre-Treatment Liver-Related Factors on Clinical Outcomes after CAR T-Cell Therapy for Lymphoma

Identifying the Barriers of Clinical Trial Access after CAR T-Cell Therapy in Relapsed/Refractory Large B-Cell Lymphoma

Longer Follow-up of Golcadomide (GOLCA), a Cereblon E3 Ligase Modulator (CELMoD™) Agent ± Rituximab (RTX), in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Three-Factor Prediction Model for Grade 2+ Cytokine Release Syndrome in Large B-Cell Lymphoma Patients Receiving Epcoritamab Monotherapy

Lisocabtagene Maraleucel (liso-cel) in Patients (pts) with Relapsed or Refractory (R/R) Follicular Lymphoma (FL): Transcend FL 2-Year Follow-up

Treatment Patterns and Real World Outcomes with Clinical Trials for Patients with Follicular Lymphoma across Lines of Therapy

Real-World Effectiveness of Tafasitamab (Tafa) for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) in the United States

Real-World Predictors of Financial Toxicity in Patients with Lymphoma

Cell-Intrinsic and Immune-Mediated Effects in Lymphoma Patients Treated with Golcadomide and Associations with Treatment Outcome

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only